All Posts Tagged Tag: ‘Pharmaceuticals’

Merck Drug Fails Major Clinical Trial

Merck, a major U.S. pharmaceutical company, announced this week that its drug “Tredaptive” has failed a clinical trial. The trial was meant to test the drug for its ability to improve patients’ heart health by increasing their levels of “good” cholesterol. The trial, conducted at Oxford University and funded by Merck, looked at 25,673 patients at high risk for heart …

Read More

Cholesterol Meds Most Effective With Exercise, Shows Study

A new study shows that cholesterol-lowering drugs have a more significant effect when combined with exercise. Though both the drugs and exercise lower the chances of premature death for people with high colesterol, their combined use staved off death better than either on its own. The study, published in the journal The Lancet, looked at more than 10,000 U.S. veterans, …

Read More

Grapefruit Warning For Medications Expanded

A review published this week in the Canadian Medical Association Journal (CMAJ) warns that while the number of prescription drugs that have adverse effects from interactions with grapefruit are increasing, many doctors may be unaware of the effects. The review was performed by the same researchers who discovered the adverse interactions over 20 years ago. “Many of the drugs that …

Read More

Diabetes Treatment Shown to Improve Memory For Alzheimer’s Patients

A new study shows that a drug used to treat insulin resistance in diabetics could improve cognitive performance in some people with Alzheimer’s disease. In the study, published this week in the Journal of Neuroscience, the drug rosiglitazone was used on mice that have been genetically engineered to serve as models for Alzheimer’s disease. Researchers found that treatment with the …

Read More

Asthma Drug Rejected by U.K.’s NICE

The U.K.’s National Institute for Health and Clinical Excellence (NICE) this weekend issued a draft guidance stating that it does not recommend omalizumab, an asthma medication marketed as Xolair by Novartis Pharmaceuticals. NICE is a U.K. health authority that publishes guidelines for the National Health Service. Omalizumab currently has a U.K. marketing authorization as an add-on therapy for persistent allergic …

Read More

Arthritis Drug Approved by the U.S. FDA

The U.S. Food and Drug Administration this week approved Xeljanz (tofacitinib) for the treatment of moderate to severe rheumatoid arthritis (RA) in adults who have not responded to methotrexate. The twice-daily pill works by blocking molecules known as “Janus kinases.” The approval was based on the medication’s approval was based on its demonstrated effectiveness and safety in seven clinical trials. …

Read More

Multiple Sclerosis Drug ‘Reboots’ the Immune System

New trials show that a cancer drug can be an effective treatment for multiple sclerosis (MS) by ‘rebooting’ patients’ immune systems. The results of two phase III clinical trials were published today in the journal The Lancet. The trials, sponsored by Genzyme and Bayer Schering Pharma, found that for patients who recently relapsed, using a drug called alemtuzumab saw new …

Read More

Cholesterol Drug Wins FDA Recommendation

Isis Pharmaceuticals recently announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) found the company’s drug, Kynamro (the trade name for mipomersen sodium) has been demonstrated to exhibit “sufficient” efficacy and safety for the treatment of Homozygous Familial Hypercholesterolemia (HoFH). HoFH is an aggressive, genetic cardiovascular disorder characterized by high levels of …

Read More

Cancer Treatment Kevetrin Begins Clinical Trials

Today the Cellceutix Corporation announced that its new anti-cancer drug candidate Kevetrin will soon be entering clinical trials at the Harvard Cancer Center’s Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. Cellceutix is a biopharmaceutical company focused on small molecule drugs for the treatment of “unmet” medical conditions, such as drug-resistant cancers and autoimmune diseases. Kevetrin is Cellceutix’s name …

Read More

Cancer Treatment for Colorectal Cancer Approved

The U.S. Food and Drug Administration (FDA) this week announced that it has approved a new drug for the treatment of colorectal cancer. According to the U.S. Centers for Disease Control and Prevention (CDC), colorectal cancer is the third most common cancer for both men and women, and the third leading cause of cancer deaths in the U.S. The drug …

Read More

New MS Treatment Shown to Reduce Relapses

Two phase 3 clinical trials have shown that oral doses of a drug called BG-12 show “significant” and “clinically meaningful” reductions in multiple sclerosis (MS) relapses and brain lesions in people with a relapsing form of MS. The active ingredient in BG-12 is the compound dimethyl fumarate. The trials, which were published yesterday in the New England Journal of Medicine, …

Read More

Multiple Sclerosis Pill Approved by U.S. FDA

The U.S. FDA this week approved a once-a-day pill for the treatment of multiple sclerosis (MS). The pill, being branded as “Aubagio” by Sanofi S.A., is specifically for the treatment of adults with relapsing forms of MS. “In a clinical trial, the relapse rate for patients using Aubagio was about 30 percent lower than the rate for those taking a …

Read More

Page 2 of 3«123»